Compare Occidental Petroleum Corporation (OXY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs 10X Genomics Inc — how do they compare? Occidental Petroleum Corporation trades at $57.47 (market cap $56.20B), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: Occidental Petroleum Corporation is far larger — about 10.3× 10X Genomics Inc's market cap, and Occidental Petroleum Corporation pays a 1.84% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| OXY | TXG | |
|---|---|---|
Market Cap | $56.20B | $5.48B |
Sector | Energy | Health |
52-Week High | $66.24 | $47.20 |
52-Week Low | $38.92 | $11.34 |
Enterprise Value | $77.28B | $5.02B |
Dividend Yield | 1.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $56.50, up 2.99% for the day, with a bullish technical signal and strong earnings beats in recent quarters. The company maintains solid profitability with a 22.42% net income margin and robust cash flow from operations of $10.53B in 2025. Recent news highlights Permian Basin growth and capital spending cuts, while analyst consensus leans bullish with a $65.38 price target.
OXY presents upside potential driven by earnings momentum and debt reduction, but faces risks from oil price volatility and declining revenue trends. The stock's elevated P/E ratio of 74.58 warrants caution, though institutional support and strategic positioning in carbon capture technology offer long-term value. Current levels near resistance at $57 require monitoring for breakout confirmation.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
